Douglas W Sborov
Alliance for Clinical Trials in Oncology
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Douglas W Sborov as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:35 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07605416 · Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM TrialNational Cancer Institute (NCI) · recruiting · Plasma Cell Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:35 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Alliance for Clinical Trials in Oncology Member Site CoreU10CA180821 · NCI · ALLIANCE NCTN FOUNDATION · PI Evanthia Galanis · fiscal years 2014 to 2026Named on NCT07605416
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:35 UTC. The ranking covers the 200 most relevant of 15 PubMed records, and a shared surname and initials can bring in a namesake. All 15 on PubMed
- 625 citationsRCR 29.5
- 160 citationsRCR 15.0
- A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.Clin Cancer Res · 201476 citationsRCR 2.0
- 60 citationsRCR 15.5
- A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas.Leuk Lymphoma · 201748 citationsRCR 1.5
- Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.Blood Cancer J · 202435 citationsRCR 4.3
- Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.Blood Cancer J · 202435 citationsRCR 4.2
- Associations of High-Dose Melphalan Pharmacokinetics and Outcomes in the Setting of a Randomized Cryotherapy Trial.Clin Pharmacol Ther · 201731 citationsRCR 1.2
- Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.Br J Haematol · 202224 citationsRCR 1.8
- Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.Br J Haematol · 201521 citationsRCR 0.6